<DOC>
	<DOCNO>NCT02170220</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics vortioxetine metabolite Lu AA34443 Lu AA39835 follow single oral dose administration vortioxetine 5 mg participant severe hepatic impairment compare healthy participant .</brief_summary>
	<brief_title>Pharmacokinetics , Safety Tolerability Vortioxetine Normal Hepatic Function Severe Hepatic Impairment</brief_title>
	<detailed_description>The drug test study call vortioxetine . Vortioxetine test ass move throughout body people severe hepatic impairment compare people normal hepatic function . This study look lab result people take vortioxetine . The study enrol 12 participant . Participants assign one two treatment group base hepatic function ( severe hepatic impairment vs. normal hepatic function ) . All participant group receive one vortioxetine 5-mg tablet . This single-center trial conduct United States . The overall time participate study 58 day . Participants make 2 visit clinic , include one 12-day period confinement clinic , contact telephone 30 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>General : 1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Is age 18 75 year , inclusive , time informed consent first study medication dose . 4 . Weighs least 50 kg body mass index ( BMI ) 19 38 kg/m^2 , inclusive Screening . 5 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 30 day last dose . 6 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study . 7 . Has rest pulse heart rate ( read electrocardiogram [ ECG ] ) 51 100 beat per minute ( bpm ) , inclusive . For healthy participant good physical condition age 18 45 year , inclusive , low limit 45 bpm . 8 . Has negative result screen fecal occult blood screen . Healthy Participants ( Normal Hepatic Function ) : 9 . The participant , opinion investigator , good health determine prestudy physical examination , medical history , vital sign , ECG , result blood biochemistry , hematology , serology test , urinalysis . Participants severe hepatic impairment : 10 . Has classify severe hepatic impairment define ChildPugh classification system . 11 . Has case record note demonstrate stable biochemistry judge investigator prior Screening . 12 . Has case record note demonstrate physical sign consistent clinical diagnosis liver impairment ( eg , liver firmness palpation , splenic enlargement , spider angioma , palmar erythema , parotid hypertrophy , testicular atrophy , ascites , gynecomastia ) . 13 . For participant hepatic encephalopathy , condition , investigator 's opinion , interfere participant 's ability provide appropriate inform consent . ( Participants severe encephalopathy receive score 3 4 . The score reflect degree encephalopathy treatment . This documented source . ) General : 1 . Has receive investigational compound within 45 day prior first dose study medication . 2 . Has receive vortioxetine ( Lu AA21004 ) previous clinical study therapeutic agent . 3 . Is immediate family member , study site employee , dependant relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . Has receive donate 400 mL blood blood product within 45 day precede begin study plan donate blood study . 5 . Has history hypersensitivity allergy vortioxetine relate compound mechanism action include associated excipients . 6 . Has medical history , presence , gastric duodenal ulceration , gastritis , recent head injury trauma within 1 week Screening , extensive ecchymosis , hemoptysis , gingival bleeding , hematemesis , repeat significant nose bleeds , periorbital hematoma , retinal detachment , menorrhagia , hematuria , melena . 7 . Has acute , clinically significant illness within 30 day prior first dose study medication . 8 . Has history abdominal surgery ( except laparoscopic cholecystectomy uncomplicated appendectomy ) , thoracic , nonperipheral vascular surgery within 6 month prior study medication . 9 . Has history cancer , basal cell Stage 1 squamous cell carcinoma skin remission least 5 year prior first dose study drug . 10 . Has take medication , supplement food product except allow hepatically impaired participant , approve Takeda casebycase basis . 11 . If female , participant pregnant lactate intend become pregnant , , within 30 day participate study ; intend donate ova time period . 12 . If male , participant intend donate sperm course study 30 day thereafter . 13 . Has poor peripheral venous access . 14 . Has serum creatinine level great 1.5 mg/dL Screening Day 1 ( Checkin ) . 15 . Has active stage 3 4 encephalopathy . 16 . Has diastolic blood pressure &gt; 100 mm Hg systolic blood pressure &gt; 160 mm Hg ( supine ) Screening Day 1 . 17 . Has orthostatic blood pressure ≥25 mm Hg ( base difference supine stand [ 1 minute ] systolic blood pressure ) Screening Day 1 . 18 . Has know history human immunodeficiency virus infection . 19 . Has positive test result hepatitis B surface antigen . 20 . The participant 's correct QT interval ( QTc , Bazett correction ) &gt; 450 millisecond ( msec ) men &gt; 470 msec woman Screening Checkin read printout ECG evaluate investigator . 21 . Has history clinical manifestation significant illness renal insufficiency , hematologic , pulmonary , cardiovascular , gastrointestinal , neurological , rheumatologic , urologic , immunologic , infectious , skin subcutaneous tissue disorder , psychiatric mood disorder ( include past suicide attempt ) . For hepatically impaired participant , previously know condition associate liver disease exclude . 22 . Exercises extensively his/her normal life , , marathon running , triathlons , physical sport contest level , etc . 23 . Answers positive suicidal ideation and/or suicidal behavior question administration ColumbiaSuicide Severity Rating Scale ( CSSRS ) [ 79 ] Screening . 24 . Is unwilling unable comply protocol schedule appointment . 25 . Is unable understand verbal and/or write English language certify translation approve informed consent available . 26 . The participant , opinion investigator , unlikely comply clinical trial protocol deem unsuitable reason . 27 . Has history drug abuse ( define illicit drug use ) history alcohol abuse ( define regular daily consumption 2 alcoholic unit per day ) within 1 year prior Screening Visit ( 1 unit=250 mL beer 20 mL spirit 1 glass [ 118 mL ] wine ) . Participants severe hepatic dysfunction test positive urine drug screen due prescription drug use allow participate approve principal investigator sponsor 's medical monitor . Healthy Participants ( Normal Hepatic Function ) : 28 . Has clinically significant abnormal finding medical history , physical exam , ECG , clinical laboratory test , opinion investigator , preclude study participation . 29 . Has hepatic and/or endocrine disorder . 30 . Has positive test result antibody hepatitis C virus . 31 . Has alanine transaminase aspartate transaminase level great 1.5 × upper limit normal ( ULN ) Screening Day 1 ( Checkin ) , active liver disease , active gall bladder disease , jaundice . 32 . Has predisposition easy bruise bleeding , anemia , thrombocytopenia , know history , history firstdegree relative , bleed disorder ( include Von Willebrand 's disease hemophilia A B ) . 33 . Has positive test fecal occult blood . Participants severe hepatic impairment : 34 . Has clinically significant laboratory abnormality except parameter influence hepatic impairment . 35 . Has serious illness except control hypertension diabetes problem associate primary diagnosis hepatic impairment disease approve principal investigator sponsor 's medical monitor . 36 . Has clinical exacerbation liver disease ( i.e , abdominal pain , nausea , vomit , anorexia , fever ) within 2week period administration study drug . 37 . Has clinical demonstrable , massive , tense ascites . 38 . Has evidence acute viral hepatitis within 1 month prior administration study medication . 39 . Has evidence hepatorenal syndrome . 40 . Has know history bleed disorder ( include Von Willebrand 's disease hemophilia A B ) . 41 . Has active alcohol abuse dependence define Diagnostic Statistical Manual Mental Disorders , Fourth Edition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>